Moreover, no therapies are currently available to target GTF2I. KIT mutations occur in 6 to 20% of thymic carcinomas although only a few tumors harbor an activating KIT mutation and therefore only some patients may benefit from receptor tyrosine kinase inhibitors (12–14). This evidence concerns the gene GTF2I and thymic carcinoma.